Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.52 |
| ▸ | CDK7 | P50613 | 10/20 | 0.50 |
| ▸ | CDK9 | P50750 | 10/20 | 0.50 |
| ▸ | ROS1 | P08922 | 4/20 | 0.46 |
| ▸ | MET | P08581 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17879579 | 0.93 | ALK (0.56) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL29666260 | 0.85 | ALK (0.67) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL375643 | 0.85 | ALK (0.67) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL1018125 | 0.83 | ALK (0.53) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL31512671 | 0.81 | ALK (0.71) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL2061222 | 0.81 | ALK (0.71) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL375715 | 0.79 | ALK (0.55) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL29904751 | 0.79 | CDK7 (0.61) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL375003 | 0.79 | CDK7 (0.61) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL30598344 | 0.79 | ALK (0.57) | ALKCDK7CDK9ROS1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, PDCD1 | ALK 1358/4885CDK7 101/4885CDK9 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.